An early event of EGFR mutation in pleomorphic carcinoma of the lung

International Journal of Clinical Oncology

Volumn 16, Issue 6, 2011, Pages 770-773

  Saitoh, Miyako ^a   Niijima, Mafumi ^b   Takiguchi, Yuichi ^a   Hiroshima, Kenzo ^c   Fujita, Yoshihiko ^d   Nishio, Kazuto ^d   Tatsumi, Koichiro ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION CHIBA MEDICAL CENTER   (Japan)

^c Tokyo Women s Medical University   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EGFR mutation; EGFR TKI; Pleomorphic carcinoma of the lung

Indexed keywords

CARBOPLATIN; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG TREATMENT FAILURE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE MUTATION; GENERAL CONDITION DETERIORATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; PLEURA EFFUSION; PRIORITY JOURNAL; RECEPTOR GENE; THORACOTOMY; THORAX RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; POINT MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84855191782     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0247-x     Document Type: Article

References (18)

1. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib New Engl J Med 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
2. JG Paez PA Janne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
3. W Pao V Miller M Zakowski, et al. 2004 EGF receptor gene mutations are common in lung cancers from "never smokers", are associated with sensitivity of tumors to gefitinib, erlotinib Proc Natl Acad Sci USA 101 13306 13311 15329413 10.1073/pnas.0405220101 1:CAS:528:DC%2BD2cXnvFems70%3D (Pubitemid 39209661)
4. PA Janne JA Engelman BE Johnson 2005 Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment, tumor biology J Clin Oncol 23 3227 3234 15886310 10.1200/JCO.2005.09.985 1:CAS:528:DC%2BD2MXltVWis70%3D (Pubitemid 46211347)
5. PA Janne BE Johnson 2006 Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors Clin Cancer Res 12 4416s 4420s 16857820 10.1158/1078-0432.CCR-06-0555 (Pubitemid 44197191)
6. K Sugio H Uramoto K Ono, et al. 2006 Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking Br J Cancer 94 896 903 16552419 10.1038/sj.bjc.6603040 1:CAS:528:DC%2BD28Xis1Gktbo%3D
7. S Kobayashi TJ Boggon T Dayaram, et al. 2005 EGFR mutation, resistance of non-small-cell lung cancer to gefitinib New Engl J Med 352 786 792 15728811 10.1056/NEJMoa044238 1:CAS:528:DC%2BD2MXhsFCiurk%3D (Pubitemid 40271173)
8. JA Engelman K Zejnullahu T Mitsudomi, et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039 1043 17463250 10.1126/science.1141478 1:CAS:528:DC%2BD2sXltlOjt7g%3D (Pubitemid 46799492)
9. J Bean C Brennan J-Y Shih, et al. 2007 MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci USA 104 20932 20937 18093943 10.1073/pnas.0710370104 1:CAS:528:DC%2BD1cXktlyhsg%3D%3D
10. S Yano W Wang Q Li, et al. 2008 Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 68 9479 9487 19010923 10.1158/0008-5472.CAN-08-1643 1:CAS:528:DC%2BD1cXhtlOmt7jE
11. H Kimura Y Fujiwara T Sone, et al. 2006 High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients Cancer Sci 97 642 648 16827805 10.1111/j.1349-7006. 2006.00216.x 1:CAS:528:DC%2BD28XmsVOntLs%3D (Pubitemid 44056613)
12. H Kimura M Suminoe K Kasahara, et al. 2007 Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) Br J Cancer 97 778 784 17848912 10.1038/sj.bjc.6603949 1:CAS:528:DC%2BD2sXhtVWksLzP (Pubitemid 47396294)
13. A Hamburger S Salmon 1977 Primary bioassay of human tumor stem cells Science 197 461 463 560061 10.1126/science.560061 1:STN:280:DyaE2s3hsF2htA%3D%3D
14. T Reya SJ Morrison MF Clarke, et al. 2001 Stem cells, cancer, cancer stem cells Nature 414 105 111 11689955 10.1038/35102167 1:CAS:528: DC%2BD3MXot1ahs7c%3D (Pubitemid 33041634)
15. A Ushiki T Koizumi N Kobayashi, et al. 2009 Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib, clinical outcome Jpn J Clin Oncol 39 267 270 19155283 10.1093/jjco/hyn155
16. K Kaira Y Horie E Ayabe, et al. 2010 Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis J Thorac Oncol 5 460 465 20107421 10.1097/JTO.0b013e3181ce3e3c
17. S Toyooka Y Yatabe M Tokumo, et al. 2006 Mutations of epidermal growth factor receptor, K-ras genes in adenosquamous carcinoma of the lung Int J Cancer 118 1588 1590 16187277 10.1002/ijc.21500 1:CAS:528:DC%2BD28XhslCqsbg%3D
18. A Tatematsu J Shimizu Y Murakami, et al. 2008 Epidermal growth factor receptor mutations in small cell lung cancer Clin Cancer Res 14 6092 6096 18829487 10.1158/1078-0432.CCR-08-0332 1:CAS:528:DC%2BD1cXhtF2nurvM